by Roberto — In the last few years, im­munother­apy has quickly be­come the emerg­ing "fourth pil­lar" in can­cer treat­ment, join­ing surgery, ra­di­a­tion ther­apy and chemother­apy. The ba­sic con­cept be­hind the de­vel­op­ment of im­mune check­point in­hibitors as anti-can­cer ther­a­peu­tics is that ac­ti­vat­ing the im­mune sys­tem can some­times re­sult in the body rid­ding it­self of ma­lig­nant cells.